Oramed Pharmaceuticals Inc risk profile
64 Stretched several inputs deteriorating together
Measured 21 October 2026 from ORMP's filed statements. Recomputed nightly.
64 (Stretched), driven by Cash conversion at 98, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 57 | Elevated | Volatile | One-year price volatility — 52.1% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 98 | Acute | Stable | Capital spending against operating cash — -0.00x |
| Leverage and coverage | 0 | Contained | Easing | Net debt to EBITDA — -0.60x |
| Competitive position | 77 | Stretched | Stable | Operating-margin gap against peers — -742.5 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Oramed Pharmaceuticals Inc